Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank92
3Y CAGR+3.4%
5Y CAGR+3.0%
Year-over-Year Change
Selling, general, and administrative expenses
3Y CAGR
+3.4%/yr
vs +1.9%/yr prior
5Y CAGR
+3.0%/yr
Consistent
Acceleration
+1.5pp
Accelerating
Percentile
P92
Near historical high
vs 5Y Ago
1.2x
Modest growth
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $22.90M | +32.8% |
| 2024 | $17.24M | +67.4% |
| 2023 | $10.30M | -50.3% |
| 2022 | $20.71M | -16.0% |
| 2021 | $24.66M | +24.8% |
| 2020 | $19.76M | +70.2% |
| 2019 | $11.61M | -39.5% |
| 2018 | $19.20M | +115.4% |
| 2017 | $8.91M | +25.9% |
| 2016 | $7.08M | - |